| Summary: | Tuberculosis (TB) basically has two types: active and latent infections. The current
vaccination against TB, which is Bacillus Calmette-Guerin (BCG), is unable to
provide protection with high efficacy against active TB while showing no protection
against latent infection. The administration of BCG vaccination is systemic. Thus,
the creation of mucosal tuberculosis vaccines with a focus on the protein constituent
has become an area of research interest. The development of mucosal vaccines is
difficult due to the nature of the mucosal system. In a previous study, our group
developed the mucosal vaccine by combining the three different epitopes of TB,
namely Ag85b, latency-associated protein (Acr), and resuscitation-promoting factor
(Rpf) from Mycobacterium tuberculosis (Mtb), linked with secretory
immunoglobulin A (sIgA). The construct has been cloned into the genome of the
adeno-associated viral vector before being transduced into the mammary gland of the
pregnant goat. Acr and Rpf are important components that are involved in the
reactivation of dormant Mtb. Together with Ag85b, they have become important
targets for the development of a new TB mucosal vaccine with the goal of preventing
the reactivation of dormant tubercle bacilli associated with latent tuberculosis. In this
study, the expression of the immunodominant epitope in the milk of the goat was
evaluated using western blot with Rb pAb to Mycobacterium tuberculosis Ag85b.
The result shows that a band at approximately 75 kDa was detected, indicating that
the epitopes were successfully expressed in milk. The expression of chimeric
proteins in different concentrations of goat milk is significant at p < 0.05.
|
|---|